Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: nitric oxide-based COX-2 inhibitors and NSAIDs - NitroMed

Drug Profile

Research programme: nitric oxide-based COX-2 inhibitors and NSAIDs - NitroMed

Alternative Names: NMI 150; NMI 153; NMI 159; NMI 161; NMI 172; NMI 377; NMI-1182

Latest Information Update: 19 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NitroMed
  • Class Naphthalenes; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Pain

Most Recent Events

  • 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
  • 20 Sep 2005 Data presented at the 230th National Meeting of the American Chemical Society (230th ACS-2005) have been added to the Inflammation pharmacodynamics section
  • 31 Dec 2004 Merck & Co. has terminated its licence for nitric oxide-based COX-2 inhibitors and NSAIDs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top